Rome, Nov 15. (Adnkronos Health) – “Significant progress has been made in breast cancer treatment, not only in therapies but also in diagnostics. Today, in fact, we have molecularly targeted drugs available, which act on specific characteristics of the tumor. To choose the most suitable treatment, it is therefore necessary to know the molecular characteristics of the disease through specific tests, which must be guaranteed to all patients. However, patients and caregivers are not very aware of the opportunities offered by precision oncology.” So said Massimo Di Maio, president of the Italian Association of Medical Oncology, to Adnkronos Health, commenting on the data from a survey promoted by the Aiom Foundation and presented today at the XXVIII Aiom national congress, which concludes today in Rome.
“Until a few years ago – explains Di Maio – the main problem with access to care concerned the availability of drugs, reimbursement times, and costs. These aspects remain important, but today there is also a prior issue: timely access to diagnostic tests. If molecular tests are not efficiently available, some patients risk not being able to access potentially effective therapies, simply because they are not identified as potential beneficiaries. Today there are very advanced diagnostic tools, capable of simultaneously analyzing numerous genes through specific panels and identifying various molecular alterations. It is not necessary for every hospital to have its own laboratory: samples can be transferred to other centers. The important thing is that the organization is efficient and that the results arrive quickly, because important therapeutic choices depend on this information.”
The point is precisely this: “it is not enough to guarantee all patients access to a specific drug; it is also necessary to ensure the possibility of performing the test needed to understand who can benefit from it. When we talk about equitable innovation, we are therefore talking about equal access for everyone not only to drugs, but also to molecular diagnostics,” he concludes.